Aerpio Announces Amended Licensing Deal with Gossamer Bio on Product Candidate GB004; deal restructured
In a deal potentially worth up to $420mm, Aerpio Pharmaceuticals Inc. licensed Gossamer Bio Inc. exclusive global rights to develop and commercialize AKB4924 and related compounds for inflammatory bowel diseases including ulcerative colitis and Crohn’s disease.
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com